Pharmaceutical company Cascade Chemistry has commenced construction of a new $14m facility to increase its current Good Manufacturing Practices standards and procedures (cGMP) pharmaceutical manufacturing capacity.
The new facilities are designed to manufacture active pharmaceutical ingredients (APIs) under cGMP.
Go deeper with GlobalData
Initially, the 28,000ft2 building will include five suites for Phase 1 and Phase 2 cGMP manufacturing with flow hydrogenation and reactors up to 400 litres.
The company stated that the additional capacity for API Phase 3, as well as the commercial scale of cGMP manufacturing up to 1,000 litres, is scheduled to be added next year.
Slated to be operational in the first quarter of 2022, these new facilities are expected to almost triple the company’s floor space.
They will also increase Cascade Chemistry’s manufacturing capacity of APIs for clinical trial materials and ultimately commercial production.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAdditionally, the expansion plans also include 2,200ft2 of new analytical labs, a robust quality system and additional office space.
Further, a 7,000ft2 second building will be reserved for future expansion.
Cascade Chemistry president Jeremiah Marsden said: “This $14 million expansion reflects our growing success as a reliable, experienced and flexible outsourcing partner with exceptional chemistry problem-solving expertise.
“Our customers are increasingly requesting our assistance in producing APIs for their clinical trials, and demand has outstripped our cGMP manufacturing capacity.
“We were fortunate to acquire two suitable buildings just 10 minutes from our current facility, and construction of new cGMP manufacturing suites that will greatly increase our clinical trial API production capacity is now underway.”
—————————————————————————————————————–
Eugene, OR-based Cascade Chemistry initiated construction of a $14 million facility to significantly increase its cGMP pharmaceutical manufacturing capacity. (Credit: Business Wire.)
